🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 70 (from laksa180)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa070.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/\')), getAhrefsUnparsedNoserviceFromURL(\'https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/www.rheumatologyadvisor.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/","crawl_time":1776051442,"first_indexed_time":1757080995,"http_code":200,"src_unparsed":"com,rheumatologyadvisor!www,\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/ s443","src_root_hash":"5233655969898461270","history_drop_reason":null,"meta_title":"Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval - Rheumatology Advisor","meta_descriptions":["The FDA has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax and mNexspike."],"attrs_boilerpipe_text":"The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2.\nThe Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax\n®\nand\nmNexspike\n®\n.\nThe updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the\npreferred strain\nat the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025. \nSpikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older. \nModerna’s\nnew COVID-19 vaccine mNexspike\nis approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from\nCOVID-19\nand all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL.\nModerna’s updated vaccines are expected to be available in the coming days.\nThis article originally appeared on\nMPR\nReferences:\nModerna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025.\nhttps:\/\/feeds.issuerdirect.com\/news-release.html?newsid=6729249760870595&symbol=MRNA\n.\nSpikevax. Package insert. Moderna; 2025. Accessed August 27, 2025.\nhttps:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/5efa7d9d-05e8-46b5-945a-637c2867bd00\/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf\n.\nmNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025.\nhttps:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf\n.","attrs_markdown":"Menu SECTIONS\n\n- [News](https:\/\/www.rheumatologyadvisor.com\/news\/)\n- [Features](https:\/\/www.rheumatologyadvisor.com\/features\/)\n- [CME](https:\/\/www.rheumatologyadvisor.com\/rheumatology-cme-courses\/)\n- [Clinical Tools](https:\/\/www.rheumatologyadvisor.com\/clinical-tools\/)\n- [Conferences](https:\/\/www.rheumatologyadvisor.com\/conferences\/)\n- [Special Collections](https:\/\/www.rheumatologyadvisor.com\/special-collections\/)\n- [Multimedia](https:\/\/www.rheumatologyadvisor.com\/multimedia\/)\n- [Diagnosis & Disease Info](https:\/\/www.rheumatologyadvisor.com\/ddi\/)\n- [Clinical Quiz](https:\/\/www.rheumatologyadvisor.com\/hm-article-type\/clinical-quiz\/)\n- [Fact Sheets](https:\/\/www.rheumatologyadvisor.com\/hm-article-type\/fact-sheets\/)\n\n- [Topics]()\n  - [Axial Spondyloarthritis](https:\/\/www.rheumatologyadvisor.com\/subjects\/axial-spondyloarthritis\/)\n  - [Connective Tissue Disease](https:\/\/www.rheumatologyadvisor.com\/subjects\/connective-tissue-disease\/)\n  - [Crystal Arthropathies](https:\/\/www.rheumatologyadvisor.com\/subjects\/crystal-arthropathies\/)\n  - [Diseases of Bone and Cartilage](https:\/\/www.rheumatologyadvisor.com\/subjects\/diseases-of-bone-and-cartilage\/)\n  - [General Medicine](https:\/\/www.rheumatologyadvisor.com\/subjects\/general-medicine\/)\n  - [General Rheumatology](https:\/\/www.rheumatologyadvisor.com\/subjects\/general-rheumatology\/)\n  - [Infection in Rheumatic Disease](https:\/\/www.rheumatologyadvisor.com\/subjects\/infection-in-rheumatic-disease\/)\n  - [Musculoskeletal Pain](https:\/\/www.rheumatologyadvisor.com\/subjects\/musculoskeletal-pain\/)\n  - [Myositis](https:\/\/www.rheumatologyadvisor.com\/subjects\/myositis\/)\n  - [Osteoarthritis](https:\/\/www.rheumatologyadvisor.com\/subjects\/osteoarthritis\/)\n  - [Pediatric Rheumatology](https:\/\/www.rheumatologyadvisor.com\/subjects\/pediatric-rheumatology\/)\n  - [Practice Management](https:\/\/www.rheumatologyadvisor.com\/subjects\/practice-management\/)\n  - [Psoriatic Arthritis](https:\/\/www.rheumatologyadvisor.com\/subjects\/psoriatic-arthritis\/)\n  - [Rheumatoid Arthritis](https:\/\/www.rheumatologyadvisor.com\/subjects\/rheumatoid-arthritis\/)\n  - [Sjögren Syndrome](https:\/\/www.rheumatologyadvisor.com\/subjects\/sjogren-syndrome\/)\n  - [Systemic Lupus Erythematosus](https:\/\/www.rheumatologyadvisor.com\/subjects\/systemic-lupus-erythematosus\/)\n  - [Vasculitis](https:\/\/www.rheumatologyadvisor.com\/subjects\/vasculitis\/)\n\n- [Haymarket Medical Network](https:\/\/www.rheumatologyadvisor.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/)\n  - [Cancer Therapy Advisor](https:\/\/www.cancertherapyadvisor.com\/)\n  - [Clinical Advisor](https:\/\/www.clinicaladvisor.com\/)\n  - [Clinical Pain Advisor](https:\/\/www.clinicalpainadvisor.com\/)\n  - [Dermatology Advisor](https:\/\/www.dermatologyadvisor.com\/)\n  - [Endocrinology Advisor](https:\/\/www.endocrinologyadvisor.com\/)\n  - [Gastroenterology Advisor](https:\/\/www.gastroenterologyadvisor.com\/)\n  - [Hematology Advisor](https:\/\/www.hematologyadvisor.com\/)\n  - [Infectious Disease Advisor](https:\/\/www.infectiousdiseaseadvisor.com\/)\n  - [Medical Bag](https:\/\/www.medicalbag.com\/)\n  - [MPR](https:\/\/www.empr.com\/)\n  - [Neurology Advisor](https:\/\/www.neurologyadvisor.com\/)\n  - [Oncology Nurse Advisor](https:\/\/www.oncologynurseadvisor.com\/)\n  - [Ophthalmology Advisor](https:\/\/www.ophthalmologyadvisor.com\/)\n  - [Optometry Advisor](https:\/\/www.optometryadvisor.com\/)\n  - [Psychiatry Advisor](https:\/\/www.psychiatryadvisor.com\/)\n  - [Pulmonology Advisor](https:\/\/www.pulmonologyadvisor.com\/)\n  - [Rare Disease Advisor](https:\/\/www.rarediseaseadvisor.com\/)\n  - [Renal and Urology News](https:\/\/www.renalandurologynews.com\/)\n  - [Rheumatology Advisor](https:\/\/www.rheumatologyadvisor.com\/)\n  - [Sleep Wake Advisor](https:\/\/www.sleepwakeadvisor.com\/)\n  - [The Cardiology Advisor](https:\/\/www.thecardiologyadvisor.com\/)\n  - [Vaccine Advisor](https:\/\/www.vaccineadvisor.com\/)\n\n[![rheumatologyadvisor logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/logos\/rheumatologyadvisor.svg)](https:\/\/www.rheumatologyadvisor.com\/)\n\nPart of the [![HMN logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/HMN-logo-1line.svg)](https:\/\/www.haymarketmedicalnetwork.com\/about)\n\n- [News and Features](https:\/\/www.rheumatologyadvisor.com\/news-and-features\/)\n- [CME](https:\/\/www.rheumatologyadvisor.com\/rheumatology-cme-courses\/)\n- [Conferences](https:\/\/www.rheumatologyadvisor.com\/conferences\/)\n- [Clinical Tools](https:\/\/www.rheumatologyadvisor.com\/clinical-tools\/)\n- [Special Collections](https:\/\/www.rheumatologyadvisor.com\/special-collections\/)\n- [Multimedia](https:\/\/www.rheumatologyadvisor.com\/multimedia\/)\n\nShare this article\n\n- [![facebook share](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/facebook-social-share.svg) Share on Facebook](https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.rheumatologyadvisor.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/)\n- [![twitter share](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/twitter-social-share-x.svg) Share on Twitter](https:\/\/twitter.com\/share?url=https:\/\/www.rheumatologyadvisor.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/&text=Moderna%E2%80%99s%202025-2026%20COVID-19%20Vaccines%20Get%20FDA%20Approval)\n- [![linkedin share](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/linkedin-social-share.svg) Share on LinkedIn](http:\/\/www.linkedin.com\/shareArticle?mini=true&url=https:\/\/www.rheumatologyadvisor.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/)\n- [![email](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/email-social-share.svg) Share by Email](https:\/\/www.rheumatologyadvisor.com\/cdn-cgi\/l\/email-protection#734c200611191610074e3e1c1716011d1291f3ea00564143414341465e41434145564143303c253a375e424a564143251210101a1d1600564143341607564143353732564143320303011c05121f555043404b48311c170a4e301b1610185641431c0607564143071b1a005641431201071a101f165641431207495641435b1b07070300495c5c0404045d011b16061e12071c1f1c140a1217051a001c015d101c1e5c1d1604005c1e1c1716011d12005e414341465e414341455e101c051a175e424a5e051210101a1d16005e1416075e1517125e120303011c05121f5c)\n- [![print](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/print-social-share.svg) Print]()\n\n[General Medicine](https:\/\/www.rheumatologyadvisor.com\/subjects\/general-medicine\/)\n\n# Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n![](https:\/\/secure.gravatar.com\/avatar\/b4fabf20be27ebd40843144495f7b32c2f51ae0eeeac62335464e52aab99c362?s=96&d=mm&r=g)[Diana Ernst, RPh](https:\/\/www.rheumatologyadvisor.com\/author\/dianaernst)\n\n\\|\n\nPublish Date\n\nSeptember 5, 2025\n\n![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/key-point_icon.svg) The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2.\n\nThe Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax® and [mNexspike](https:\/\/www.rheumatologyadvisor.com\/news\/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike\/)®.\n\nThe updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the [preferred strain](https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025) at the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025.\n\nSpikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older.\n\nModerna’s [new COVID-19 vaccine mNexspike](https:\/\/www.empr.com\/news\/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike\/) is approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from [COVID-19](https:\/\/www.rheumatologyadvisor.com\/features\/loneliness-and-social-isolation-in-rheumatology\/) and all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL.\n\nModerna’s updated vaccines are expected to be available in the coming days.\n\n**This article originally appeared on [MPR](https:\/\/www.empr.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/)**\n\nReferences:\n\n1. Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025. <https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=6729249760870595&symbol=MRNA>.\n2. Spikevax. Package insert. Moderna; 2025. Accessed August 27, 2025. <https:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/5efa7d9d-05e8-46b5-945a-637c2867bd00\/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf>.\n3. mNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025. <https:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf>.\n\n- ![Related Icon](https:\/\/www.rheumatologyadvisor.com\/wp-content\/plugins\/hm-related-recommendations-manager\/assets\/images\/related-icon.svg)\n  \n  #### Related News\n  \n  - [March 2026: Notable Drug Approvals](https:\/\/www.rheumatologyadvisor.com\/news\/march-2026-notable-drug-approvals\/)\n  - [High Dose Spinraza Receives FDA Approval for Spinal Muscular Atrophy](https:\/\/www.rheumatologyadvisor.com\/news\/high-dose-spinraza-receives-fda-approval-for-spinal-muscular-atrophy\/)\n  - [FDA Approves Teva's Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review](https:\/\/www.rheumatologyadvisor.com\/news\/fda-approves-tevas-prolia-biosimilar-ponlimsi-accepts-xolair-biosimilar-for-review\/)\n- ![Top Picks Icon](https:\/\/www.rheumatologyadvisor.com\/wp-content\/plugins\/hm-related-recommendations-manager\/assets\/images\/top-pick-icon.svg)\n  \n  #### Top Picks\n  from our\n  \n  Haymarket Medical Network\n  \n  1. [COVID-19 Lockdown Measures Linked to Higher Risk for Psychotic Experiences in Adults](https:\/\/www.psychiatryadvisor.com\/news\/covid-19-lockdown-measures-linked-to-higher-risk-for-psychotic-experiences-in-adults\/)\n  2. [FDA Drug Approval Decisions Expected in May 2026](https:\/\/www.empr.com\/news\/fda-drug-approval-decisions-expected-in-may-2026\/)\n  3. [FDA Approves Generic Dapagliflozin for Adults With T2D](https:\/\/www.empr.com\/news\/fda-approves-generic-dapagliflozin-for-adults-with-t2d\/)\n\n[![rheumatologyadvisor logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/logos\/rheumatologyadvisor.svg)](https:\/\/www.rheumatologyadvisor.com\/)\n\n[![facebook logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/facebook.svg)](https:\/\/www.facebook.com\/rheumatologyadvisor\/) [![linkedin logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/linkedin.svg)](https:\/\/www.linkedin.com\/company\/rheumatology-advisor\/) [![twitter-x logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/twitter-x.svg)](https:\/\/twitter.com\/RheumAdvisor)\n\nRheumatology Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient outcomes.\n\nCookie Settings\n\n- [ABOUT](https:\/\/www.haymarketmedicalnetwork.com\/about\/)\n- [ADVERTISE](https:\/\/haymarketmed.wufoo.com\/forms\/qvg9cou12lsqdi\/)\n- [CONNECT](https:\/\/www.haymarketmedicalnetwork.com\/connect\/)\n\n[![HMN logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/HMN-newlogo.svg)](https:\/\/www.haymarketmedicalnetwork.com\/about)\n\nRemarkable healthcare content\n\n[Cancer Therapy Advisor](https:\/\/www.cancertherapyadvisor.com\/)\n\n[Clinical Advisor](https:\/\/www.clinicaladvisor.com\/)\n\n[Clinical Pain Advisor](https:\/\/www.clinicalpainadvisor.com\/)\n\n[Dermatology Advisor](https:\/\/www.dermatologyadvisor.com\/)\n\n[Endocrinology Advisor](https:\/\/www.endocrinologyadvisor.com\/)\n\n[Gastroenterology Advisor](https:\/\/www.gastroenterologyadvisor.com\/)\n\n[Hematology Advisor](https:\/\/www.hematologyadvisor.com\/)\n\n[Infectious Disease Advisor](https:\/\/www.infectiousdiseaseadvisor.com\/)\n\n[McKnight’s Home Care](https:\/\/www.mcknightshomecare.com\/)\n\n[McKnight’s Long-term Care News](https:\/\/www.mcknights.com\/)\n\n[McKnight’s Senior Living](https:\/\/www.mcknightsseniorliving.com\/)\n\n[Medical Bag](https:\/\/www.medicalbag.com\/)\n\n[MPR](https:\/\/www.empr.com\/)\n\n[myCME](https:\/\/www.mycme.com\/)\n\n[NACE](https:\/\/www.naceonline.com\/)\n\n[Neurology Advisor](https:\/\/www.neurologyadvisor.com\/)\n\n[Oncology Nurse Advisor](https:\/\/www.oncologynurseadvisor.com\/)\n\n[Ophthalmology Advisor](https:\/\/www.ophthalmologyadvisor.com\/)\n\n[Optometry Advisor](https:\/\/www.optometryadvisor.com\/)\n\n[Psychiatry Advisor](https:\/\/www.psychiatryadvisor.com\/)\n\n[Pulmonology Advisor](https:\/\/www.pulmonologyadvisor.com\/)\n\n[Rare Disease Advisor](https:\/\/www.rarediseaseadvisor.com\/)\n\n[Renal and Urology News](https:\/\/www.renalandurologynews.com\/)\n\n[Rheumatology Advisor](https:\/\/www.rheumatologyadvisor.com\/)\n\n[Sleep Wake Advisor](https:\/\/www.sleepwakeadvisor.com\/)\n\n[The Cardiology Advisor](https:\/\/www.thecardiologyadvisor.com\/)\n\n[Vaccine Advisor](https:\/\/www.vaccineadvisor.com\/)\n\n![haymarket logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/haymarket_b_corp.svg)\n\nCopyright © 2026 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s [Privacy Policy](https:\/\/www.haymarketmediaus.com\/haymarket-media-inc-privacy-policy\/) and [Terms & Conditions.](https:\/\/www.haymarketmediaus.com\/haymarket-media-inc-terms-and-conditions-of-service\/)\n\n![close logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/close.svg)  Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n\nLoading... ![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/spinner.svg)\n\n![close logo](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/close.svg)  Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n\nLoading... ![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/spinner.svg)\n\n![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/plugins\/hm-gating-and-metering-manager\/assets\/svg\/close.svg)  Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n\n![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/plugins\/hm-gating-and-metering-manager\/assets\/svg\/close.svg)  Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n\nLoading... ![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/spinner.svg)\n\n![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/plugins\/hm-gating-and-metering-manager\/assets\/svg\/close.svg)  Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval\n\nLoading... ![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/haymarket\/assets\/svg\/src\/spinner.svg)","attrs_readable_markdown":"![](https:\/\/www.rheumatologyadvisor.com\/wp-content\/themes\/hm-advisor-child\/assets\/svg\/key-point_icon.svg) The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2.\n\nThe Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax® and [mNexspike](https:\/\/www.rheumatologyadvisor.com\/news\/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike\/)®.\n\nThe updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the [preferred strain](https:\/\/www.fda.gov\/vaccines-blood-biologics\/industry-biologics\/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025) at the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025.\n\nSpikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older.\n\nModerna’s [new COVID-19 vaccine mNexspike](https:\/\/www.empr.com\/news\/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike\/) is approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from [COVID-19](https:\/\/www.rheumatologyadvisor.com\/features\/loneliness-and-social-isolation-in-rheumatology\/) and all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL.\n\nModerna’s updated vaccines are expected to be available in the coming days.\n\n**This article originally appeared on [MPR](https:\/\/www.empr.com\/news\/modernas-2025-2026-covid-19-vaccines-get-fda-approval\/)**\n\nReferences:\n\n1. Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025. <https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=6729249760870595&symbol=MRNA>.\n2. Spikevax. Package insert. Moderna; 2025. Accessed August 27, 2025. <https:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/5efa7d9d-05e8-46b5-945a-637c2867bd00\/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf>.\n3. mNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025. <https:\/\/static.modernatx.com\/pm\/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6\/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf>.","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

4 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.2 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/
Last Crawled	2026-04-13 03:37:22 (4 days ago)
First Indexed	2025-09-05 14:03:15 (7 months ago)
HTTP Status Code	200
Meta Title	Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval - Rheumatology Advisor
Meta Description	The FDA has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax and mNexspike.
Meta Canonical	null
Boilerpipe Text	The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2. The Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax ® and mNexspike ® . The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the preferred strain at the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025. Spikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older. Moderna’s new COVID-19 vaccine mNexspike is approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL. Moderna’s updated vaccines are expected to be available in the coming days. This article originally appeared on MPR References: Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025. https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&symbol=MRNA . Spikevax. Package insert. Moderna; 2025. Accessed August 27, 2025. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/5efa7d9d-05e8-46b5-945a-637c2867bd00/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf . mNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025. https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf .
Markdown	Menu SECTIONS - [News](https://www.rheumatologyadvisor.com/news/) - [Features](https://www.rheumatologyadvisor.com/features/) - [CME](https://www.rheumatologyadvisor.com/rheumatology-cme-courses/) - [Clinical Tools](https://www.rheumatologyadvisor.com/clinical-tools/) - [Conferences](https://www.rheumatologyadvisor.com/conferences/) - [Special Collections](https://www.rheumatologyadvisor.com/special-collections/) - [Multimedia](https://www.rheumatologyadvisor.com/multimedia/) - [Diagnosis & Disease Info](https://www.rheumatologyadvisor.com/ddi/) - [Clinical Quiz](https://www.rheumatologyadvisor.com/hm-article-type/clinical-quiz/) - [Fact Sheets](https://www.rheumatologyadvisor.com/hm-article-type/fact-sheets/) - [Topics]() - [Axial Spondyloarthritis](https://www.rheumatologyadvisor.com/subjects/axial-spondyloarthritis/) - [Connective Tissue Disease](https://www.rheumatologyadvisor.com/subjects/connective-tissue-disease/) - [Crystal Arthropathies](https://www.rheumatologyadvisor.com/subjects/crystal-arthropathies/) - [Diseases of Bone and Cartilage](https://www.rheumatologyadvisor.com/subjects/diseases-of-bone-and-cartilage/) - [General Medicine](https://www.rheumatologyadvisor.com/subjects/general-medicine/) - [General Rheumatology](https://www.rheumatologyadvisor.com/subjects/general-rheumatology/) - [Infection in Rheumatic Disease](https://www.rheumatologyadvisor.com/subjects/infection-in-rheumatic-disease/) - [Musculoskeletal Pain](https://www.rheumatologyadvisor.com/subjects/musculoskeletal-pain/) - [Myositis](https://www.rheumatologyadvisor.com/subjects/myositis/) - [Osteoarthritis](https://www.rheumatologyadvisor.com/subjects/osteoarthritis/) - [Pediatric Rheumatology](https://www.rheumatologyadvisor.com/subjects/pediatric-rheumatology/) - [Practice Management](https://www.rheumatologyadvisor.com/subjects/practice-management/) - [Psoriatic Arthritis](https://www.rheumatologyadvisor.com/subjects/psoriatic-arthritis/) - [Rheumatoid Arthritis](https://www.rheumatologyadvisor.com/subjects/rheumatoid-arthritis/) - [Sjögren Syndrome](https://www.rheumatologyadvisor.com/subjects/sjogren-syndrome/) - [Systemic Lupus Erythematosus](https://www.rheumatologyadvisor.com/subjects/systemic-lupus-erythematosus/) - [Vasculitis](https://www.rheumatologyadvisor.com/subjects/vasculitis/) - [Haymarket Medical Network](https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/) - [Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/) - [Clinical Advisor](https://www.clinicaladvisor.com/) - [Clinical Pain Advisor](https://www.clinicalpainadvisor.com/) - [Dermatology Advisor](https://www.dermatologyadvisor.com/) - [Endocrinology Advisor](https://www.endocrinologyadvisor.com/) - [Gastroenterology Advisor](https://www.gastroenterologyadvisor.com/) - [Hematology Advisor](https://www.hematologyadvisor.com/) - [Infectious Disease Advisor](https://www.infectiousdiseaseadvisor.com/) - [Medical Bag](https://www.medicalbag.com/) - [MPR](https://www.empr.com/) - [Neurology Advisor](https://www.neurologyadvisor.com/) - [Oncology Nurse Advisor](https://www.oncologynurseadvisor.com/) - [Ophthalmology Advisor](https://www.ophthalmologyadvisor.com/) - [Optometry Advisor](https://www.optometryadvisor.com/) - [Psychiatry Advisor](https://www.psychiatryadvisor.com/) - [Pulmonology Advisor](https://www.pulmonologyadvisor.com/) - [Rare Disease Advisor](https://www.rarediseaseadvisor.com/) - [Renal and Urology News](https://www.renalandurologynews.com/) - [Rheumatology Advisor](https://www.rheumatologyadvisor.com/) - [Sleep Wake Advisor](https://www.sleepwakeadvisor.com/) - [The Cardiology Advisor](https://www.thecardiologyadvisor.com/) - [Vaccine Advisor](https://www.vaccineadvisor.com/) [![rheumatologyadvisor logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/logos/rheumatologyadvisor.svg)](https://www.rheumatologyadvisor.com/) Part of the [![HMN logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/HMN-logo-1line.svg)](https://www.haymarketmedicalnetwork.com/about) - [News and Features](https://www.rheumatologyadvisor.com/news-and-features/) - [CME](https://www.rheumatologyadvisor.com/rheumatology-cme-courses/) - [Conferences](https://www.rheumatologyadvisor.com/conferences/) - [Clinical Tools](https://www.rheumatologyadvisor.com/clinical-tools/) - [Special Collections](https://www.rheumatologyadvisor.com/special-collections/) - [Multimedia](https://www.rheumatologyadvisor.com/multimedia/) Share this article - [![facebook share](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/facebook-social-share.svg) Share on Facebook](https://www.facebook.com/sharer.php?u=https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/) - [![twitter share](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/twitter-social-share-x.svg) Share on Twitter](https://twitter.com/share?url=https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/&text=Moderna%E2%80%99s%202025-2026%20COVID-19%20Vaccines%20Get%20FDA%20Approval) - [![linkedin share](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/linkedin-social-share.svg) Share on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://www.rheumatologyadvisor.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/) - [![email](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/email-social-share.svg) Share by Email](https://www.rheumatologyadvisor.com/cdn-cgi/l/email-protection#734c200611191610074e3e1c1716011d1291f3ea00564143414341465e41434145564143303c253a375e424a564143251210101a1d1600564143341607564143353732564143320303011c05121f555043404b48311c170a4e301b1610185641431c0607564143071b1a005641431201071a101f165641431207495641435b1b07070300495c5c0404045d011b16061e12071c1f1c140a1217051a001c015d101c1e5c1d1604005c1e1c1716011d12005e414341465e414341455e101c051a175e424a5e051210101a1d16005e1416075e1517125e120303011c05121f5c) - [![print](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/print-social-share.svg) Print]() [General Medicine](https://www.rheumatologyadvisor.com/subjects/general-medicine/) # Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval ![](https://secure.gravatar.com/avatar/b4fabf20be27ebd40843144495f7b32c2f51ae0eeeac62335464e52aab99c362?s=96&d=mm&r=g)[Diana Ernst, RPh](https://www.rheumatologyadvisor.com/author/dianaernst) \\| Publish Date September 5, 2025 ![](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/key-point_icon.svg) The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2. The Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax® and [mNexspike](https://www.rheumatologyadvisor.com/news/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike/)®. The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the [preferred strain](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025) at the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025. Spikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older. Moderna’s [new COVID-19 vaccine mNexspike](https://www.empr.com/news/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike/) is approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from [COVID-19](https://www.rheumatologyadvisor.com/features/loneliness-and-social-isolation-in-rheumatology/) and all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL. Moderna’s updated vaccines are expected to be available in the coming days. This article originally appeared on [MPR](https://www.empr.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/) References: 1. Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025. <https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&symbol=MRNA>. 2. Spikevax. Package insert. Moderna; 2025. Accessed August 27, 2025. <https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/5efa7d9d-05e8-46b5-945a-637c2867bd00/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf>. 3. mNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025. <https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf>. - ![Related Icon](https://www.rheumatologyadvisor.com/wp-content/plugins/hm-related-recommendations-manager/assets/images/related-icon.svg) #### Related News - [March 2026: Notable Drug Approvals](https://www.rheumatologyadvisor.com/news/march-2026-notable-drug-approvals/) - [High Dose Spinraza Receives FDA Approval for Spinal Muscular Atrophy](https://www.rheumatologyadvisor.com/news/high-dose-spinraza-receives-fda-approval-for-spinal-muscular-atrophy/) - [FDA Approves Teva's Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review](https://www.rheumatologyadvisor.com/news/fda-approves-tevas-prolia-biosimilar-ponlimsi-accepts-xolair-biosimilar-for-review/) - ![Top Picks Icon](https://www.rheumatologyadvisor.com/wp-content/plugins/hm-related-recommendations-manager/assets/images/top-pick-icon.svg) #### Top Picks from our Haymarket Medical Network 1. [COVID-19 Lockdown Measures Linked to Higher Risk for Psychotic Experiences in Adults](https://www.psychiatryadvisor.com/news/covid-19-lockdown-measures-linked-to-higher-risk-for-psychotic-experiences-in-adults/) 2. [FDA Drug Approval Decisions Expected in May 2026](https://www.empr.com/news/fda-drug-approval-decisions-expected-in-may-2026/) 3. [FDA Approves Generic Dapagliflozin for Adults With T2D](https://www.empr.com/news/fda-approves-generic-dapagliflozin-for-adults-with-t2d/) [![rheumatologyadvisor logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/logos/rheumatologyadvisor.svg)](https://www.rheumatologyadvisor.com/) [![facebook logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/facebook.svg)](https://www.facebook.com/rheumatologyadvisor/) [![linkedin logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/linkedin.svg)](https://www.linkedin.com/company/rheumatology-advisor/) [![twitter-x logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/twitter-x.svg)](https://twitter.com/RheumAdvisor) Rheumatology Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient outcomes. Cookie Settings - [ABOUT](https://www.haymarketmedicalnetwork.com/about/) - [ADVERTISE](https://haymarketmed.wufoo.com/forms/qvg9cou12lsqdi/) - [CONNECT](https://www.haymarketmedicalnetwork.com/connect/) [![HMN logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/HMN-newlogo.svg)](https://www.haymarketmedicalnetwork.com/about) Remarkable healthcare content [Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/) [Clinical Advisor](https://www.clinicaladvisor.com/) [Clinical Pain Advisor](https://www.clinicalpainadvisor.com/) [Dermatology Advisor](https://www.dermatologyadvisor.com/) [Endocrinology Advisor](https://www.endocrinologyadvisor.com/) [Gastroenterology Advisor](https://www.gastroenterologyadvisor.com/) [Hematology Advisor](https://www.hematologyadvisor.com/) [Infectious Disease Advisor](https://www.infectiousdiseaseadvisor.com/) [McKnight’s Home Care](https://www.mcknightshomecare.com/) [McKnight’s Long-term Care News](https://www.mcknights.com/) [McKnight’s Senior Living](https://www.mcknightsseniorliving.com/) [Medical Bag](https://www.medicalbag.com/) [MPR](https://www.empr.com/) [myCME](https://www.mycme.com/) [NACE](https://www.naceonline.com/) [Neurology Advisor](https://www.neurologyadvisor.com/) [Oncology Nurse Advisor](https://www.oncologynurseadvisor.com/) [Ophthalmology Advisor](https://www.ophthalmologyadvisor.com/) [Optometry Advisor](https://www.optometryadvisor.com/) [Psychiatry Advisor](https://www.psychiatryadvisor.com/) [Pulmonology Advisor](https://www.pulmonologyadvisor.com/) [Rare Disease Advisor](https://www.rarediseaseadvisor.com/) [Renal and Urology News](https://www.renalandurologynews.com/) [Rheumatology Advisor](https://www.rheumatologyadvisor.com/) [Sleep Wake Advisor](https://www.sleepwakeadvisor.com/) [The Cardiology Advisor](https://www.thecardiologyadvisor.com/) [Vaccine Advisor](https://www.vaccineadvisor.com/) ![haymarket logo](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/haymarket_b_corp.svg) Copyright © 2026 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s [Privacy Policy](https://www.haymarketmediaus.com/haymarket-media-inc-privacy-policy/) and [Terms & Conditions.](https://www.haymarketmediaus.com/haymarket-media-inc-terms-and-conditions-of-service/) ![close logo](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/close.svg) Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval Loading... ![](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg) ![close logo](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/close.svg) Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval Loading... ![](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg) ![](https://www.rheumatologyadvisor.com/wp-content/plugins/hm-gating-and-metering-manager/assets/svg/close.svg) Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval ![](https://www.rheumatologyadvisor.com/wp-content/plugins/hm-gating-and-metering-manager/assets/svg/close.svg) Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval Loading... ![](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg) ![](https://www.rheumatologyadvisor.com/wp-content/plugins/hm-gating-and-metering-manager/assets/svg/close.svg) Close more info about Moderna’s 2025-2026 COVID-19 Vaccines Get FDA Approval Loading... ![](https://www.rheumatologyadvisor.com/wp-content/themes/haymarket/assets/svg/src/spinner.svg)
Readable Markdown	![](https://www.rheumatologyadvisor.com/wp-content/themes/hm-advisor-child/assets/svg/key-point_icon.svg) The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2. The Food and Drug Administration (FDA) has approved the 2025-2026 formulations of Moderna’s COVID-19 vaccines Spikevax® and [mNexspike](https://www.rheumatologyadvisor.com/news/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike/)®. The updated mRNA vaccines target the LP.8.1 variant of SARS-CoV-2, which was selected as the [preferred strain](https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2025-2026-formula-use-united-states-beginning-fall-2025) at the FDA’s Vaccines and Related Biological Products Advisory Committee meeting in May 2025. Spikevax is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19 and all adults 65 years of age and older. The product is supplied in single-dose prefilled syringes containing 1 dose of either 0.25mL for children 6 months through 11 years and 0.5mL for individuals aged 12 years and older. Moderna’s [new COVID-19 vaccine mNexspike](https://www.empr.com/news/fda-approves-modernas-next-generation-covid-19-vaccine-mnexspike/) is approved for individuals 12 through 64 years of age with at least 1 underlying condition that puts them at high risk for severe outcomes from [COVID-19](https://www.rheumatologyadvisor.com/features/loneliness-and-social-isolation-in-rheumatology/) and all adults 65 years of age and older. The vaccine is supplied in a single-dose prefilled syringe containing 1 dose of 0.2mL. Moderna’s updated vaccines are expected to be available in the coming days. This article originally appeared on [MPR](https://www.empr.com/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/) References: 1. Moderna receives US FDA approval for updated COVID-19 vaccines targeting LP.8.1 variant of SARS-CoV-2. News release. Moderna. August 27, 2025. <https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&symbol=MRNA>. 2. Spikevax. Package insert. Moderna; 2025. Accessed August 27, 2025. <https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/5efa7d9d-05e8-46b5-945a-637c2867bd00/5efa7d9d-05e8-46b5-945a-637c2867bd00_viewable_rendition__v.pdf>. 3. mNexspike. Package insert. Moderna; 2025. Accessed August 27, 2025. <https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6/9f00fca4-1dca-4c9e-9bdd-d21a1c0bf5c6_viewable_rendition__v.pdf>.
Shard	70 (laksa)
Root Hash	5233655969898461270
Unparsed URL	com,rheumatologyadvisor!www,/news/modernas-2025-2026-covid-19-vaccines-get-fda-approval/ s443